Last edition
News about Clinical Trials
UK Health Security Agency and Stablepharma report positive Phase I results for SPVX02, a fridge-free Tetanus and Diphtheria vaccine stable at 30°C for 24 months.
Clinical Trials | 17/03/2026 | By News Bureau
Merck Showcases New Cardio-Pulmonary Data at ACC.26
Merck presented late-breaking data from phase-III and phase-II trials at ACC.26, highlighting advances in its cardio-pulmonary pipeline, including an investigational oral PCSK9 inhibitor and therapies for pulmonary hypertension.
Clinical Trials | 17/03/2026 | By News Bureau | 149
Meiji Seika Pharma Initiates Phase I Trial of ME3241 PD-1 Agonist Antibody for Autoimmune Diseases
Meiji Seika Pharma Co., Ltd. has launched a Phase I clinical trial of ME3241, a novel anti-PD-1 agonist antibody developed with Foundation for Biomedical Research and Innovation at Kobe for autoimmune disease treatment.
Clinical Trials | 16/03/2026 | By News Bureau | 205
Immutep Limited will discontinue the Phase III TACTI-004 trial of eftilagimod alfa in first-line Non-Small Cell Lung Cancer after an interim analysis by the monitoring committee found the study unlikely to meet endpoints.
Clinical Trials | 16/03/2026 | By News Bureau | 124
Phase IIa MAST trial of EnteroBiotix’s microbiome therapy EBX-102-02 completes enrolment of 50 patients undergoing allogeneic stem cell transplantation to assess microbiome restoration and transplant outcomes.
Clinical Trials | 12/03/2026 | By News Bureau | 145
IDEAYA Biosciences Enrolls First Patient in Phase I Trial of IDE892 for MTAP-Deleted Solid Tumours
IDEAYA Biosciences has initiated a Phase I clinical trial of IDE892, a PRMT5 inhibitor, for MTAP-deleted cancers including Non-Small Cell Lung Cancer and Pancreatic Cancer.
Clinical Trials | 11/03/2026 | By News Bureau | 247
Aisa Pharma presented Phase II RECONNOITER trial results showing AISA-021 improved attack-free days and reduced duration of Raynaud’s attacks in systemic sclerosis patients at the World Systemic Sclerosis Congress.
Clinical Trials | 10/03/2026 | By News Bureau | 118
Roche Reports Update on PERSEVERA Breast Cancer Trial
Roche reported that the Phase III persevERA study in ER-positive advanced breast cancer did not meet its primary endpoint, though giredestrant plus palbociclib showed numerical improvement and a tolerable safety profile.
Clinical Trials | 09/03/2026 | By News Bureau | 115
Dyne Therapeutics Reports Positive Results from Z-Rostudirsen DMD Study
Dyne Therapeutics reported new 24-month data from the DELIVER trial showing Z-rostudirsen improved cardiopulmonary function in patients with Duchenne Muscular Dystrophy (DMD), building on earlier findings of sustained functional benefits across multiple clinical measures.
Clinical Trials | 09/03/2026 | By News Bureau | 117
HUTCHMED Starts Global Trial of HMPL-A580 for Solid Tumours
HUTCHMED has initiated a global clinical trial of HMPL-A580, a PI3K/PIKK-EGFR ATTC candidate, in patients with solid tumours. The study marks the second clinical programme from its next-generation ATTC platform, targeting both PAM pathway and EGFR signaling to enhance therapeutic synergy.
Clinical Trials | 06/03/2026 | By News Bureau | 113
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy